Shockwave Intervention for Enhanced Wound Healing in No-touch Pedicle Saphenous Vein Graft Harvesting for Coronary Artery Bypass Grafting

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorMedical University Innsbruck

About this trial

The aim of this trial is to apply shockwaves to the leg wound after saphenous vein harvesting and closure in order to reduce the occurrence of postoperative wound healing complications following coronary artery bypass grafting using venous grafts.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Male or female patients > 18 years

Isolated CABG procedure in the need of 2 or more venous grafts

Elective or urgent cases

Median sternotomy approach

Disqualifiers

History of venous stripping or ligation

Uncontrolled Diabetes mellitus (HbA1c ≥ 9 %)

Enrolled in other therapeutic or interventional trial

Hemodynamically unstable

Trial design

Design model

Parallel

Treatments tested in this trial

  • Shockwave treatment

    Device

    The shockwave device will be set to an energy flux density of 0.1 mJ/mm² at 5 Hz, with approximately 25 impulses per centimeter of wound length. This means that one centimeter of the wound will be treated for 5 seconds. The shockwave treatment will then be carried out, with each centimeter of the wound area treated for 5 seconds using gentle circular motions.

  • Sham treatment

    Device

    The applicator will not be connected to the shockwave device. The applicator treatment will then be carried out, with each centimeter of the wound area treated for 5 seconds using gentle circular motions.

Treatment groups

120 Participants
are divided into 2 treatment groups
Group A: Treatment groupActive comparator 1 intervention
Group B: Sham groupSham comparator 1 intervention

Trial outcomes

Primary outcomes

1

Wound Healing Disturbance

We defined the occurrence of a wound healing complication as followed: Definition of Surgical Site Infection (SSI) The SSI definition is in accordance with the guidelines of the center for disease control and their recommendations for superficial incisional SSI: * Date of event occurs within 30 days following the operative procedure AND involves only skin and subcutaneous tissue of the incision AND * Patient has at least one of the following: * Purulent drainage from the superficial incision * Organism(s) identified from an aseptically-obtained specimen from the superficial incision or subcutaneous tissue by a culture or non-culture based microbiologic testing method which is performed for purposes of clinical diagnosis or treatment * Superficial incision that is deliberately opened by a sur

Time frame
30 days after surgery

Secondary outcomes

1

Bates-Jensen Wound Assessment Tool

Difference in the Bates-Jensen Wound Assessment Tool (BWAT) score. The BWAT is a validated instrument used to assess wound healing, consisting of 13 scored items related to wound size, depth, edges, undermining, necrotic tissue, exudate, skin color, peripheral tissue, granulation, and epithelialization. Each item is scored from 1 (best) to 5 (worst). The total score ranges from 13 (completely healed wound) to 65 (most severe wound condition). Higher scores indicate worse wound status.

Time frame
From randomization to the end of participation at 180 days
2

Change in EQ-5D-5L Index Score

Difference in the EQ-5D-5L index score, a standardized measure of health-related quality of life developed by the EuroQol Group. The EQ-5D-5L index score ranges from -0.594 to 1.000, where higher scores indicate better health status. A score of 1 represents full health, 0 represents a health state equivalent to death, and negative values represent health states considered worse than death.

Time frame
From randomization to end of study participation at 180 days
3

Unscheduled visits

Number of unscheduled outpatient visits

Time frame
From randomization to end of study participation at 180 days
4

Surgical revision

Rate of surgical revisions due to wound healing complications, except for bleeding

Time frame
From randomization to end of study participation at 180 days

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.